Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | GRIA1 | P42261 | 1/20 | 0.51 |
| ▸ | HDAC4 | P56524 | 4/20 | 0.50 |
| ▸ | HDAC3 | O15379 | 3/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 3/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 3/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 3/20 | 0.50 |
| ▸ | HDAC11 | Q96DB2 | 3/20 | 0.50 |
| ▸ | HDAC8 | Q9BY41 | 3/20 | 0.50 |
| ▸ | HDAC6 | Q9UBN7 | 3/20 | 0.50 |
| ▸ | HDAC9 | Q9UKV0 | 3/20 | 0.50 |
| ▸ | HDAC5 | Q9UQL6 | 3/20 | 0.50 |
| ▸ | MEF2D | Q14814 | 1/20 | 0.50 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.49 |
| ▸ | GPR132 | Q9UNW8 | 5/20 | 0.48 |
| ▸ | ECE1 | P42892 | 1/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1133842 | 1.00 | LMNA (0.51) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL2121460 | 1.00 | LMNA (0.51) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL10336284 | 0.96 | LMNA (0.52) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL10336285 | 0.96 | LMNA (0.52) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL8006880 | 0.89 | ERAP2 (0.52) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL8586993 | 0.88 | FOLH1 (0.46) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL27536574 | 0.88 | GRIA1 (0.52) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL7415827 | 0.88 | GRIA1 (0.52) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL6524155 | 0.86 | ERAP2 (0.49) | LMNAGRIA1HDAC4HDAC3HDAC1 | |
| SCHEMBL6524153 | 0.86 | ERAP2 (0.49) | LMNAGRIA1HDAC4HDAC3HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 187 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | OHIO STATE INNOVATION FOUNDATION (US) | 2025-06-17 | — | — | US | claimed |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | OHIO STATE INNOVATION FOUNDATION | 2024-02-01 | — | — | US | claimed |
| US-20230212235-A1 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2023-07-06 | — | — | US | claimed |
| EP-4085064-A1 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | Ohio State Innovation Foundation (US) | 2022-11-09 | — | — | EP | claimed |
| CN-115135665-A | Cyclic proteins comprising cell penetrating peptides | 俄亥俄州国家创新基金会 | 2022-09-30 | — | — | CN | claimed |
| WO-2022109058-A1 | NUCLEASES COMPRISING CELL PENETRATING PEPTIDE SEQUENCES | ENTRADA THERAPEUTICS, INC. (US) | 2022-05-27 | — | — | WO | claimed |
| WO-2021138397-A1 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | OHIO STATE INNOVATION FOUNDATION (US) | 2021-07-08 | — | — | WO | claimed |
| US-20210038737-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION | 2021-02-11 | — | — | US | claimed |
| EP-3746105-A2 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | Ohio State Innovation Foundation (US) | 2020-12-09 | — | — | EP | claimed |
| WO-2019148195-A2 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | OHIO STATE INNOVATION FOUNDATION (US) | 2019-08-01 | — | — | WO | claimed |
| EP-4706689-A2 | COMPOSITIONS FOR DELIVERY OF ANTISENSE COMPOUNDS | Entrada Therapeutics, Inc. (US) | 2026-03-11 | — | — | EP | disclosed |
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | Wang, Jieyi (US) | 2025-12-25 | — | — | US | disclosed |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | OHIO STATE INNOVATION FOUNDATION (US) | 2025-12-16 | — | — | US | disclosed |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | OHIO STATE INNOVATION FOUNDATION (US) | 2025-10-23 | — | — | US | disclosed |
| EP-3240570-B1 | BISPECIFIC ANTIBODIES AGAINST PLASMA KALLIKREIN AND FACTOR XII | TAKEDA PHARMACEUTICALS CO (JP) | 2025-09-24 | — | — | EP | disclosed |
| WO-1994027641-A1 | AMPLIFICATION OF THE VITAMIN B12 UPTAKE SYSTEM USING POLYMERS | BIOTECH AUSTRALIA PTY. LIMITED (AU) | 1994-12-08 | — | — | WO | disclosed |
| WO-1991019743-A2 | COMBINED TREATMENT WITH GnRH ANTAGONIST AND GnRH TO CONTROL GONADOTROPIN LEVELS IN MAMMALS | APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) | 1991-12-26 | — | — | WO | disclosed |
| EP-0377665-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE. | UNIV TEXAS (US) | 1990-07-18 | — | — | EP | disclosed |
| WO-1989009786-A1 | PEPTIDE DERIVATIVES | SANDOZ AG (CH) | 1989-10-19 | — | — | WO | disclosed |
| WO-1989001944-A1 | EFFECTIVE ANTAGONISTS OF THE LUTEINIZING HORMONE RELEASING HORMONE WHICH RELEASE NEGLIGIBLE HISTAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-03-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230212235-A1 | LOOPED PROTEINS COMPRISING CELL PENETRATING PEPTIDES | LNPEP, SPPL2B, CNBP | LMNA 1443/4885GRIA1 3903/4885HDAC4 4657/4885 |
| US-20250388669-A1 | MULTI-SPECIFIC ANTIBODIES IN USES THEREOF IN AVIDITY RECEPTOR CROSSLINKING AND IMMUNE MODULATION | TNFRSF9, FCGR3B, FCGR2A | LMNA 4148/4885GRIA1 763/4885HDAC4 3653/4885 |
| US-20250324980-A1 | COMPOSITIONS FOR DELIVERY OF AGENTS INTO PLANT CELLS | ARGLU1, PHAX, VMA21 | LMNA 1496/4885GRIA1 2182/4885HDAC4 3966/4885 |
| US-20210038737-A1 | CYCLIC PEPTIDYL INHIBITORS OF CAL-PDZ BINDING DOMAIN | CNBP, CALU, CLSPN | LMNA 3186/4885GRIA1 2583/4885HDAC4 4285/4885 |
| US-12329799-B2 | Peptidyl inhibitors of calcineurin-NFAT interaction | CHP1, NFATC1, PPP3R1 | LMNA 4484/4885GRIA1 3359/4885HDAC4 871/4885 |
| US-12496350-B2 | Cyclic peptidyl inhibitors of CAL-PDZ binding domain | CNBP, CALU, CLSPN | LMNA 3186/4885GRIA1 2583/4885HDAC4 4285/4885 |
| US-20240033318-A1 | PEPTIDYL INHIBITORS OF CALCINEURIN-NFAT INTERACTION | CHP1, NFATC1, PPP3R1 | LMNA 4484/4885GRIA1 3359/4885HDAC4 871/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.